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In Brief
Poursaitidis et al. show that EGFR and BRAF mutant cells are sensitive to ferroptosis. Sensitivity was related to activation of MAPK signaling and the generation and release of hydrogen peroxide. To show that this sensitivity can be exploited therapeutically, growth of an EGFR mutant NSCLC xenograft was inhibited by a cyst(e)ine-degrading enzyme.
INTRODUCTION
Synthetic lethal screens have led to the identification of specific cancer cell vulnerabilities Possik et al., 2014; Scholl et al., 2009 ). One such vulnerability has previously been exploited therapeutically in acute lymphoblastic leukemia (ALL), where leukemic cells lacking asparagine synthase are known to require the amino acid asparagine and apoptose following administration of asparaginase (Holleman et al., 2003; Tallal et al., 1970) . Overall amino acid abundance itself may be higher in cancerous tissue, suggesting an increased need for amino acids in some tumors (Hirayama et al., 2009; Kami et al., 2013) . In pancreatic ductal adenocarcinoma (PDAC), KRAS is thought to induce a genetic program that favors metabolism of glutamine, rendering these cells particularly sensitive to glutamine withdrawal (Son et al., 2013) . Some tumor cell lines (Scott et al., 2000) and primary tumors (Gonzalez and Byus, 1991) require exogenous arginine, indicating some selectivity in amino acid requirements. Here, we have explored the extracellular amino acid nutrient requirements of cells gene edited to introduce common oncogenic mutations. We identify a selective sensitivity to synchronous cell death by ferroptosis following deprivation of the amino acid nutrient cystine. Sensitization was found to be related to elevated mitogen-activated protein kinase (MAPK) signaling, with synchronous cell death involving hydrogen peroxide generation and release. Finally, we show that enzymatic cystine deprivation in vivo results in an inhibition of tumor growth in an EGFR mutant NSCLC xenograft model, suggesting that, by promoting ferroptosis, cystine depletion provides therapeutic benefit in some tumors.
RESULTS
EGFR Mutant HME Cells Undergo Cell Death when Deprived of the Amino Acid Nutrient Cystine Human mammary epithelial (HME) cells were gene edited to introduce common oncogenic driver mutations (epidermal (Di Nicolantonio et al., 2008) . Following culture in media deficient in specific amino acids, we measured cell viability. All lines deprived of L-cystine (cystine) exhibited some loss of viability ranging from 40% to >80%. However, EGFR and BRAF mutant HME cells were especially sensitive, with viability inhibited by >80% ( Figure 1A ). Cystine deprivation induced a widespread loss of viability in EGFR mutant, but not wild-type HME, cells, with the majority of cells exhibiting a swollen or burst morphology ( Figure 1B ). Next, we monitored EGFR mutant HME cells deprived of cystine by video time-lapse microscopy and observed rapid and synchronous cell swelling/bursting ( Figure 1C ; Movie S1). Sytox Green, a cell-impermeant nuclear stain, synchronously entered cells after cystine depletion ( Figure 1C ), indicating loss of plasma membrane integrity at <2 mM cystine ( Figure 1D ). Death was reversible upon re-supplementation of cystine for up to 10 hr but declined progressively thereafter and was not prevented by addition of D-cystine ( Figure S1A ).
Cell Death in Cystine-Deprived EGFR Mutant HME Cells Exhibits Hallmarks of Ferroptosis This type of death resembled ferroptosis, an iron-dependent non-apoptotic cell death (Dixon et al., 2012) . Because lipid reactive oxygen species (ROS) accumulation characterizes ferroptosis (Dixon et al., 2012) , we measured ROS. Fluorescenceactivated cell sorting (FACS) analysis indicated increased ROS accumulation in EGFR mutant HME cells following cystine deprivation ( Figure 1E ). EGFR mutant HME cells treated with known ferroptosis inhibitors inhibited lipid ROS generation ( Figure 1F ) and protected EGFR mutant (and BRAF mutant; Figure S1B ) cells from cell death ( Figure 1G ), as did treatment with two other antioxidants ( Figure 1H ). Finally, erastin, an inhibitor of the system x c -cystine/glutamate antiporter (Dixon et al., 2012) , also induced selective loss of viability in EGFR mutant cells (Figure 1H) . Collectively, these data indicate that cell death in EGFR mutant cells occurs by ferroptosis.
MAPK Signaling Sensitizes EGFR Mutant Cells to Cell
Death following Cystine Deprivation EGFR activation results in activation of downstream signaling cascades (Pines et al., 2010) . Ferroptosis had previously been shown to require MAPK signaling (Yagoda et al., 2007; Dixon et al., 2012) . Treatment of EGFR mutant cells for >24 hr with EGFR or MAPK (MEK and ERK1/2) inhibitors inhibited EGFR and MAPK signaling (Figures 2A and S2A ), restored normal adherens junction formation and gap junctional intercellular communication (GJIC) ( Figures 2B and 2C) , and rescued cell viability following cystine withdrawal ( Figures 2D and S2B) . Likewise, EGFR and MAPK inhibition in EGFR mutant cells inhibited ROS generation ( Figures 2E, S2C , and S2D).
Cystine Promotes Viability in EGFR Mutant HME Cells via a Glutathione-Independent Mechanism HME cells might resist ferroptosis by maintaining intracellular levels either of cystine or glutathione, the major cystine-derived antioxidant. To address the former possibility, we deprived cells of cystine and measured activation of GCN2, a sensor of amino acid depletion (Hinnebusch, 2005) . However, in both wild-type and EGFR mutant HME cells, GCN2 was equivalently activated following cystine deprivation ( Figure 3A ). Basal cystine levels were also equivalent and declined similarly in wild-type and EGFR mutant cells following extracellular cystine depletion (Figure S3A) . Recent data have suggested a role for glutaminolysis in promoting ferroptosis (Gao et al., 2015) . However, both wildtype and EGFR mutant HME cells contained similar steady-state intracellular levels of glutamine that were largely unaltered by deprivation of cystine ( Figure S3A ). Similarly, total levels of glutathione declined equivalently in wild-type and EGFR mutant HME cells following cystine deprivation ( Figure 3B ). However, Iressa-treated EGFR mutant cells accumulated more oxidized glutathione (GSSG) in comparison to untreated EGFR mutant HME cells following deprivation of cystine, suggesting that EGFR inhibition increased ROS detoxification ( Figure 3C ). Surprisingly, an inhibitor of glutathione synthesis (buthionine sulfoximine [BSO]), although also depleting glutathione levels, did not induce cell death ( Figure 3D ) nor increase ROS in EGFR mutant HME cells, unlike deprivation of cystine ( Figure S3B ). We therefore asked whether short-term deprivation of cystine, or inhibition of cystine import, acted synergistically with glutathione depletion to induce cell death. Indeed, short-term deprivation of cystine or treatment with inhibitors of the system x c -antiporter induced significantly increased cell death when combined with glutathione depletion ( Figure 3E ). Treatment with auranofin, an inhibitor of the thioredoxin reductase/thioredoxin (TRX) system (Gromer et al., 1998) implicated in reduction of cystine to cysteine (Mandal et al., 2010; Pader et al., 2014) , also synergized with glutathione depletion to promote loss of viability and lipid ROS induction ( Figures S3B and S3C) . Thus, EGFR mutant cells (D) Cell viability following titration of cystine in WT and EGFR (delE746-A750) HME cells. Histogram represents the average viability ± SD of cells cultured in various concentrations of cystine ± EGF, relative to complete media (150 mM cystine; assigned an arbitrary value of 1). (E) ROS in WT HME and EGFR (delE746-A750). (Upper panels) Total ROS measured using CMDCFDA (DCF) is shown; (lower panels) lipid ROS measured using C11 BODIPY 581/591 (C11-BODIPY) is shown. Dark traces, cells cultured in normal media for 12 hr; light traces, cells cultured in media lacking cystine for 12 hr. (F) Lipid ROS in WT and EGFR (delE746-A750) HME cells. Dark traces, cells cultured in media lacking cystine in the presence of deferoxamine (DFO; 100 mM) or ferrostatin (Fer-1; 2 mM) for 12 hr; light traces, cells cultured in media lacking cystine for 12 hr. (G) Cell viability of EGFR (delE746-A750) HME cells. Histogram is average viability ± SD cells cultured in normal media (left four bars, untreated [À] assigned an arbitrary value of 1) or media lacking cystine for 24 hr (right four bars) in the presence or absence of DFO, Fer-1, and z-VAD-fMK. (H) Cell viability (bottom histogram) and phase-contrast microscopy (upper panels) of EGFR (delE746-A750) HME cells. Histogram is average viability ± SD of three biological replicates cultured in normal media (assigned an arbitrary value of 1) or media lacking cystine for 24 hr in the presence or absence of ROS scavengers idebenone and a-tocopherol. (I) Cell viability of WT (gray bars) and EGFR (delE746-A750; black bars) HME cells. Histogram represents the average viability ± SD cells cultured in normal media or media lacking cystine for 24 hr in the presence or absence of erastin and Fer-1. oxidize less glutathione during cystine deprivation, contributing to ROS accumulation, whereas intracellular cysteine appears to play an additional role, aside from glutathione synthesis, in counteracting ROS and ferroptosis.
GPX4 Is Downregulated in EGFR Mutant HME Cells via MAPK Signaling and Modulates Sensitivity to Cell Death upon Cystine Deprivation Glutathione peroxidases (GPXs) are good candidates for mediating sensitivity to ferroptosis. GPX4 has previously been implicated in ferroptosis (Friedmann Angeli et al., 2014; Yang et al., 2014) , whereas GPX4 is induced following treatment with a BRAF inhibitor (Parmenter et al., 2014) . By immunoblotting, GPX4, but not GPX1, expression was upregulated following either EGFR or MAPK (MEK and ERK; Figure S3D ) inhibition, whereas GPX2 was not expressed in these cells ( Figure 3E ) and GPX3 is a secreted GPX expressed in the kidney (Maser et al., 1994) . Suppression of GPX4 strongly promoted cell death in both wild-type ( Figure 3G ) and Iressa-treated EGFR mutant cells ( Figure 3H ). Lipid ROS similarly increased after suppression of GPX4 ( Figure 3I ). Thus, downregulation of GPX4 in EGFR mutant HME cells conferred increased sensitivity to ferroptosis following cystine deprivation. To determine whether loss of viability was related to low levels of GPX4, we expressed Flag-GPX4 in EGFR mutant cells. Indeed, ectopic expression of GPX4 significantly increased viability following deprivation of cystine ( Figure 3J ). Thus, downregulation of GPX4 plays a key role in sensitizing EGFR mutant HME cells to ferroptosis.
Synchronous Cell Death in EGFR Mutant HME Cells Involves Generation and Release of Hydrogen Peroxide
Hydrogen peroxide is implicated in synchronous ferroptosis in kidney tubule epithelia (Linkermann et al., 2014) . Media containing soluble catalase similarly rescued viability of EGFR mutant HME cells ( Figure 3K ). Hydrogen peroxide is produced by NADPH oxidase 4 (NOX4) (Takac et al., 2011) . A NOX4 inhibitor (GKT136901; Laleu et al., 2010 ) also rescued viability, to the same degree as addition of catalase ( Figure 3K ), and inhibited lipid ROS generation ( Figure 3L ). NOX4 expression was also increased in EGFR mutant HME cells and downregulated by both EGFR and MAPK inhibition ( Figure S3E ). Finally, increased accumulation of hydrogen peroxide was detected following deprivation of cystine in EGFR mutant cells (Dickinson et al., 2010 ; Figure 3M ). Thus, hydrogen peroxide contributes to loss of viability of EGFR mutant HME cells deprived of cystine.
NSCLC Tumor Cell Lines Exhibit a Targetable Sensitivity to Ferroptosis
Mutations in the EGF receptor are found in non-small-cell lung cancers (NSCLCs) (Pao et al., 2004) that are sensitive to tyrosine kinase inhibitors (TKIs) (Paez et al., 2004) . We removed cystine from NSCLC cell lines and measured viability and MAPK activation. Of nine NSCLC cell lines tested, three with the highest MAPK signaling ( Figure S4A ) demonstrated significant loss of viability following withdrawal of cystine ( Figures 4A and S4B ). In H3255 cells (EGFR L858R mutant), sensitivity was reversed by either EGFR or MAPK inhibition, whereas in Calu-6 cells (KRAS Q61K mutant), sensitivity was reversed by MAPK, but not EGFR, inhibition ( Figure S4C ). Thus, in NSCLC cell lines, the magnitude of MAPK activation is an important determinant in sensitization to ferroptosis, rather than the nature of the specific oncogenic driver that promotes MAPK signaling. In NCI-NH1650 cells (EGFR delE746-A750), viability was restored by addition of either a-tocopherol, the ferroptosis inhibitor Fer-1 ( Figure 4B ), or Iressa (data not shown) following cystine depletion, indicating that ferroptosis and EGFR signaling were responsible for loss of viability. Surprisingly, however, MEK inhibition in these cells did not rescue viability following cystine depletion (data not shown). Thus, MAPK activation may not invariably promote sensitivity to ferroptosis, and other unknown EGFR-dependent signaling pathway(s) can substitute. Survival after treatment with TKIs in NSCLC is typically less than 1 year, with patients developing secondary EGFR mutations (Stewart et al., 2015) . We therefore sought to determine whether EGFR mutant NSCLC cells might be responsive to low levels of cystine, potentially offering additional therapeutic options utilizing a novel cystine/cysteine-degrading enzyme (cyst(e)inase; AECase) engineered from cystathionine-g-lyase (Cramer et al., 2017) . Addition of AECase reduced viability in both HME delE746-A750 EGFR or NCI-NH1650 cells ( Figures  4C and 4D ) and induced widespread uptake of Sytox Green ( Figure 4D ; Movie S2). Finally, we injected mice bearing established NCI-NH1650 xenografts with AECase. Mirroring the in vitro results, tumor growth was significantly retarded in AECase-treated groups (p = 0.0001; Figure 4E ). AECasetreated mice were also found to upregulate expression of COX2 ( Figure 4F ), indicating that they had experienced cystine depletion and initiated ferroptosis within the tumor (Yang et al., 2014) . Thus, inhibition of tumor growth can be achieved in tumors sensitive to ferroptosis by enzymatic degradation of cystine/cysteine in vivo.
DISCUSSION
Cell death by ferroptosis has been implicated in diverse processes . Previous data indicated that ferroptosis could be induced preferentially in cells overexpressing mutant RAS oncoproteins (Dixon et al., 2012; Dolma et al., 2003; Yang and Stockwell, 2008) and in some sensitive cell lines could be blocked by MAPK inhibition (Yagoda et al., 2007) . (F) Immunoblots of WT and EGFR (delE746-A750) cell lysates probed for GPX4, GPX1, GPX2, and ERK in the presence or absence of inhibitors. Relative GPX4/ ERK was calculated using ImageJ from scanned autoradiographs of three biological replicates, with the ratio in EGFR (delE746-A750) cells assigned a value of 1. (G) (Left panels) Immunoblots of WT HME lysates probed for GPX4, GPX1, and ERK1/2. (Right) Histogram of cell viability of HME cells cultured in normal media (light bars) or media lacking cystine (dark bars) for 24 hr. Histogram represents the average viability ± SD following knockdown GPX1-4. Results were expressed for each condition separately, with viability in normal media assigned a value of 1. (H) (Left panels) Phase-contrast micrographs of EGFR (delE746-A750) HME cells following transfection with control (siC) or GPX4 small interfering RNAs (siRNAs) (siGPX4) and treated with Iressa for 30 hr followed by culture in normal media or media lacking cystine for 24 hr. (Right) Histogram is viability ± SD after knockdown of GPX1-4 in Iressa-treated EGFR (delE746-A750) cells. Viability of cells cultured in normal media (light bars) or media lacking cystine (dark bars) were determined. Results were expressed for each condition separately, with viability in normal media assigned the arbitrary value of 1. (I) FACS analyses of lipid ROS in WT HME cells following knockdown of GPX1 and GPX4. Dark traces, cells cultured in normal media; light traces, cells cultured in media lacking cystine for 12 hr. (J) Histogram is shown representing the average viability ± SD following overexpression of Flag-GPX4 (Mannes et al., 2011) in EGFR (delE746-A750) cells. Viability of WT HME cells or vector-or GPX4-transfected EGFR (delE746-A750) cells cultured in normal media (light bars) or media lacking cystine (dark bars) for 16 hr is shown. Results were expressed for each condition separately, with viability in normal media assigned a value of 1. (K) (Top panels) Phase-contrast micrographs of EGFR (delE746-A750) HME cells in normal media or media deprived of cystine alone or containing catalase or GKT136901. (Bottom) Histogram representing the average viability ± SD of EGFR (delE746-A750) HME cells cultured for 24 hr in normal media (normal; assigned a value of 1) or media lacking cystine alone (ÀCys) or with BSA, catalase, superoxide dismutase (SOD), Trolox, or GKT136901 added is shown. We identify here a selective cell death of EGFR mutant cells deprived of the amino acid cystine. Death was associated with synchronous loss of plasma membrane integrity. By a variety of criteria, this mode of cell death is ferroptosis. In our model ( Figure 4G ), active MAPK signaling downstream of active EGFR can sensitize cells to ferroptosis upon cystine depletion. Sensitization involves both impaired detoxification of lipid peroxides, due to reduced expression of GPX4, and generation of hydrogen peroxide, via NOX4. A major consequence of lipid peroxidation is loss of impermeability to water (Lis et al., 2011; Wong-Ekkabut et al., 2007) , providing an explanation for the characteristic cell swelling and rupture we observe.
Sensitivity to induction of ferroptosis or cystine deprivation is likely to be modulated by additional, and possibly MAPK-independent, mechanisms, such as the utilization of the sulfur-containing amino acid methionine via the transsulfuration pathway (Hayano et al., 2016) . Our results suggest, however, the possibility of exploiting ferroptosis sensitivity in a translational manner. Tumors with sustained MAPK activation, as found in NSCLC, are likely to respond to cystine depletion in vivo by inducing ferroptosis. Our results indicate that an enzymatic approach (Cramer et al., 2017 ) may be effective in reducing cystine levels in vivo, inducing ferroptosis. Collectively, our work indicates that it might therefore be possible both to identify tumors exhibiting increased sensitivity to ferroptosis and to treat them via cycles of cystine depletion.
EXPERIMENTAL PROCEDURES Cell Culture and Treatments
The hTERT-HME cell lines were a kind gift from Prof. Alberto Bardelli (Institute for Cancer Research and Treatment, IRCC). Cells were grown in DMEM media as described (Di Nicolantonio et al., 2008) . To deprive individual amino acids, cells were washed once in DMEM media lacking all amino acids (ÀAA) and switched to specific amino-acid-free media. DMEM media used for deprivation were made from powdered AA-free DMEM (US Biological), with 10% dialyzed fetal bovine serum (FBS) and additives (Di Nicolantonio et al., 2008) . Amino acids (Sigma) at 503 concentrations in water were added at 13 concentration. All amino acids were added for complete media (+AA), with individual DMEM amino acids omitted to generate single amino-acid-deficient media. For the initial screen, 30,000 cells were plated per well in a 96-well plate and switched after 24 hr to depleted amino acid media for 72 hr. Viability was assessed in the initial screen using Calcein AM (Molecular Probes; ThermoFisher) at 1 mM for 2 hr and cells fixed for 15 min with 4% paraformaldehyde prior to analysis on a Genios plate reader and in all other experiments using the CellTiter-Glo luminescence assay (Promega).
FACS Analysis
To detect ROS, 200,000 cells were plated in 6-well plates and switched to cystine-deprived media for 12 hr prior to FACS analysis. CMDCFDA and C11-BODIPY581/591 (Molecular Probes; Thermo Fisher) were used to detect total and lipid ROS, respectively. Following deprivation of cystine for 12 hr, cells were washed with PBS, loaded with either CMDCFDA (10 mM) or C11 BODIPY (2 mM) in DPBS for 30 min, trypsinized with 0.25% Trypsin-EDTA, resuspended in PBS with 1% FBS, and analyzed using an Attune NxT flow cytometer (Thermo Fisher). Dyes were excited using a blue 488-nm laser, and emission was recorded on BL1 (530/30) for a minimum of 5,000 cells per sample.
Xenograft Tumor Model 2.53 105 NCI-H1650 cells were inoculated 1:1 in Matrigel: PBS (100 mL) by subcutaneous injection into eight non-obese diabetic (NOD) severe combined immunodeficiency (SCID) gamma male mice. Tumors were allowed to engraft and grow for 30 days (tumor volume averaged $200 mm3) and mice treated by intraperitoneal (i.p.) injection with 100 mg/kg cyst(e)inase or 100 mg/kg heatinactivated cyst(e)inase (n = 4 ea.) on day 30, with a second dose given on day 33. Mice were necropsied 24 hr after the second dose. For analyses of COX2, control and treated tumors were excised and one-half preserved in 10% neutral buffered formalin for immunohistochemistry (IHC) and the remaining half frozen in liquid nitrogen for protein extraction. For IHC, anti-COX2 from Abcam (ab15191) was used with DAB detection.
Statistical Analyses
Data were analyzed using Microsoft Excel or GraphPad Prism software (GraphPad) and are presented as mean values ± SEM. All viability data represent the mean of three biological replicates/condition. Statistical analyses were performed using two-sided Student's t test. For Kaplan-Meier plots, statistical significance was analyzed by the log rank (Mantel-Cox) test. Sample variance was not significant between control and treatment groups prior to study onset. Significance was set at p < 0.05. All data are representative of at least two independent experiments. (G) Model depicting role of activated EGFR in determining sensitivity to ferroptosis. Activated EGFR (EGFR*) stimulates MAPK signaling, reducing expression of GPX4 and inducing expression of NOX4. GPX4 utilizes reduced glutathione (GSH) derived from cystine transported via the System x ccystine-glutamate exchanger to detoxify membrane lipid peroxides (red), generating oxidized glutathione (GSSG). GSSG is recycled to GSH using reducing equivalents derived from NADPH (dashed line). Cystine can be reduced to generate cysteine that can independently detoxify ROS and may have additional functions (e.g., Briggs et al., 2016) . Lipid peroxides are generated from hydrogen peroxide (H 2 O 2 , derived from NOX4) and iron (Fe 2+ ), producing hydroxyl radicals that initiate lipid peroxidation. Lipid peroxidation leads to loss of membrane integrity, allowing uptake of water, cell swelling, and rupture.
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Supplemental Experimental Procedures siRNA knockdown and plasmid transfection
Lipofectamine 2000 (Invitrogen, ThermoFisher) was used for siRNA transfection of HME cells. 500,000 cells were plated in 6-well plates and either mock-transfected or transfected with either siCtrl or siGenome Smartpool siRNAs (Dharmacon, GE Lifesciences) to GPX1, GPX2, GPX3 and GPX4 at a final concentration of 50nM. A day after transfection cells were trypsinized and split between a 12-well plate well, with 250,000 cells, and 6 96-well plate wells, with 25,000 cells per well, for immunoblotting and viability assay respectively 3 days post transfection. For plasmid transfections, 5x105 EGFR-mutant cells were transfected in 3cm dishes with 5µg of Flag-GPX4 (p442-PL1 Flag-Strep-HA-GPX4, (Mannes et al., 2011) ) or control vector using Lipofectamine 2000 (Invitrogen, ThermoFisher). 48h after transfection wild type or transfected cells were trypsinised and replated in a 96 well plate at 20,000 cells per well and the viability experiment performed following 16h of cystine deprivation.
Western Blotting
Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 1mM EGTA, 1 mM EDTA, 1% Triton X-100, 1mM Na3VO4, 50 mM NaF, 50 mM β-glycerolphosphate, 0.27M sucrose, 0.1% beta-mercaptoethanol, Complete protease inhibitors (Roche). Protein concentration was determined using Bradford assay reagent (Biorad) and 25 µg of total protein was loaded per sample. 
GJIC scrape loading dye transfer assay
Confluent EGFR-mutant cells growing in 24-well plates were incubated with 1µM Iressa, 1µM Wortmannin, 5µM Selumetinib or 1µM DMSO (control) for 30h. Cells were then washed in Ca++-deficient PBS and transferred to PBS containing 0.5mg/mL Lucifer yellow (Sigma), 10mM glucose, 30mM HEPES buffer (Thermofisher), 0.1% BSA, 0.5 mg/mL rhodamine-dextran (Molecular Probes) and either vehicle (100mM DMSO) or 100mM carbenoxolone (Sigma). Wells were wounded via two perpendicular scratches to the monolayer and incubated for 15 minutes before being washed with PBS and fixed in 4% paraformaldehyde. Areas close to the wound margin were imaged for green fluorescence at 20X magnification using an AMG EVOS digital inverted microscope and the extent of Lucifer yellow infiltration into the monolayer was analysed using ImageJ software.
Confocal immunofluorescence microscopy
Confluent HME WT and EGFR-mutant cells growing on glass coverslips were incubated with 1µM Iressa, 1µM Wortmannin, 5µM Selumetinib or 1µM DMSO for 30h. Immunofluorescence labelling of β-catenin was undertaken as previously described (Menon et al.) and cells were imaged at 63X magnification with a confocal laser scanning microscope (Zeiss 3I LSM 800).
Additional cell treatments and microscopy
The timelapse microscope used was a Nikon TE-300 [motorised with Sutter filter wheels and a Conix block changer] equipped with a 10X phase contrast [PC] objective, encased in a Perspex 37°C incubation chamber with an insert for multi-well plates flushed with humidified, 5% CO2 air. Green fluorescence was acquired through a Nikon B-2A block split into Sutter filter wheels and a Conix block changer. Images were collected using a Hamamatsu Orca AG camera, with MicroManager software (Edelstein et al., 2010) , converting time series to an ImageJ readable format using in-house software. Cells were plated in a 6-well plate at 500,000 cells per well and grown for 3 days prior to media switch to cystine-deprived media. The plates were then transferred in the microscope stage maintained at 37°C with 5% CO2. Individual frames were obtained every 5 minutes in phase contrast and green fluorescence channels for detection of nonviable cells by Sytox Green nuclear staining used at 0.5µM concentration (Molecular Probes, Thermofisher). Apoptosis inhibitor z-VAD-fMK (Selleck) was used at 50µM. ROS scavengers Idebenone and α-Tocopherol (Sigma) were used at 1µM and 30µM respectively. Induction of ferroptotic death by erastin (Cayman Chemical) was achieved at a concentration of 2.5µg/ml. Other inhibitors used were catalase used at 1000U/ml (Sigma), superoxide dismutase used at 100U/ml (Sigma), NOX4 inhibitor GKT136901 (Aobious) at 20µM and the water-soluble vitamin E analogue Trolox at 5µM (Sigma). To determine ferroptotic cell death 10,000 EGFR HME cells were plated in a 96-well plate and allowed to grow for 3 days prior to a media shift in the presence of inhibitors of ferroptotic or apoptotic death or scavengers of reactive oxygen species. Ferroptosis inhibitor Ferrostatin1 (Fer-1, Sigma) was used at 2µM and iron chelator deferroxamine (DFO, Sigma) was used at 100µM.
To image H2O2 confluent cells were transferred to cystine-deficient media for 24 hours. Cells were then incubated with 10µM Peroxy Orange 1 (PO1, Tocris Bioscience) for 60 minutes before being washed three times in dPBS and imaged immediately at 20X magnification using an AMG EVOS digital inverted microscope. To inhibit signal transduction downstream of EGFR cells were treated for 24h prior to media switch with EGFR inhibitor Iressa (Tocris) at 1µM, MEK inhibitor Selumetinib (Selleckchem) at 5µM, PI3K inhibitor Wortmannin (Sigma) at 1µM. DMSO (Sigma) was used as a vehicle control. Additional MEK and ERK inhibitors used were U0126 (Calbiochem, 10µM), PD184352 (Sigma, 10µM), PD0325901 (Selleckchem, 1µM), GDC-0994 (ERK inhibitor, Selleckchem, 5µM) and SCH772984 (ERK inhibitor, Cayman Chemicals, 5µM). Following pretreatment for 24h cells were switched to either complete or cysteine deficient media containing the same concentration of inhibitors for 12h prior to analysis. Wortmannin was re-added at the same concentration 1hour before collection. Auranofin and S4PG were from Santa Cruz and used at 1 and 100µM, respectively. NOX4 inhibitor GKT136901 (Aobious) was used at 20µM. PEGylated AECase was used at a final concentration of 125nM, heat inactivation was performed by incubation at 95 0 C for 7 minutes, followed by brief centrifugation for 5 mins at 13,000 rpm.
For cystine titration cells were plated in triplicate cells at a final concentration of 30,000 per well in a 96-well plate (NUNC, Thermofisher) and the following day complete synthetic media containing or lacking EGF was serially diluted with DMEM lacking cystine to achieve a range of decreasing cystine concentrations. After 24h of treatment viability was determined using the CellTitre-Glo assay (Promega). An equal volume of CellTitreGlo reagent was added and the plate was vortexed at 1000 rpm for 2 minutes to allow cell lysis. The plates were then analysed on a Tecan Genios plate reader.
GSH/GSSG quantification
For the quantification of cellular reduced (GSH) and oxidised (GSSG) glutathione the method described by Rahman et al (Rahman et al., 2006) was used, which utilises the reaction of GSH with 5,5′-Dithiobis (2-nitrobenzoic acid) (DTNB) that leads to the production of the 5′-thio-2-nitrobenzoic acid (TNB) chromophore measured at 412nm (Tietze, 1969) . 1x10 6 cells were plated in 6-well plates (Greiner) and the following day treated with 200µM of BSO or switched to cystine deficient media for 8h. Cells were then washed in cold PBS, trypsinised and resuspended in 0.2ml of ice-cold extraction buffer (0.1% Triton-X and 0.6% sulfosalicylic acid in 0.1 potassium phosphate buffer with 5 mM EDTA disodium salt, pH 7.5 (KPE)). Cells were then freezethawed four times (liquid nitrogen -37°C water bath) and lysates subsequently centrifuged at 3000g for 5 min at 4 °C and supernatants collected. Protein concentrations were measured using a Bradford assay in order to express GSH and GSSG levels as nM/mg of total protein. Total glutathione (Total [GSH] = [GSH] + 2 × [GSSG]) was measured via a kinetic assay based on the reaction of DTNB with GSH and the recycling reaction by the enzyme glutathione reductase (GR) (Sigma) which in the presence of β-Nicotinamide adenine dinucleotide 2′-phosphate (β-NAPDH, Sigma) can reduce GSSG to GSH (Guntherb.H and Rost, 1966) . The rate of TNB formation was calculated by measuring 415nm absorbance in a plate reader every 30sec. GSH standards of known concentration were made from stock GSH (Sigma) and their rate of formation used to create a standard curve. For measurement of GSSG, 2-vinylpyridine (Aldrich) is added to cell lysates at 18.5 mM for 1h creating a covalent bond with GSH therefore allowing measurement only of GSSG. Excess 2-vinylpyridine was then neutralised with 75mM triethanolamine (Sigma) for 30 min (Griffith, 1980) . Levels of GSSG were determined by applying the recycling assay and measuring rate of formation of TNB as described above but using GSSG standard samples (Sigma) to create a standard curve. Reduced glutathione (GSH) could be then determined by subtraction of oxidised (GSSG) from Total glutathione (Total [GSH] = [GSH] + 2 × [GSSG]). All measurements were done in triplicate. Glutathione synthesis inhibitor buthionine sulfoximine (BSO, Santa Cruz Biotechnologies) was used at 200µM.
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